Premium
Ethanol lock therapy in pediatric hematology and oncology
Author(s) -
Wolf Joshua,
Shenep Jerry L.,
Clifford Vanessa,
Curtis Nigel,
Flynn Patricia M.
Publication year - 2013
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24249
Subject(s) - medicine , hematology , pediatric oncology , blood cancer , population , intensive care medicine , pediatric cancer , complication , catheter , central venous catheter , cancer , oncology , antibiotic therapy , surgery , antibiotics , environmental health , microbiology and biotechnology , biology
Central venous catheters are essential for treatment of cancer and hematologic disorders in children. Central line‐associated bloodstream infection (CLABSI) is the most common important complication and can lead to serious sequelae. Conventional antibiotic treatment is often unsuccessful. Ethanol lock therapy (ELT) has been shown to prevent CLABSI in various patient groups and might also be beneficial as adjunctive treatment for active infection. Efficacy and safety have not been adequately studied in the pediatric hematology/oncology population. Catheter occlusion and intraluminal clots have been reported. Routine use of ELT should not be recommended in this population until more data are available. Pediatr Blood Cancer 2013; 60: 18–25. © 2012 Wiley Periodicals, Inc.